High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4360-4367

  Lamoth, F ^a   Buclin, T ^a   Pascual, A ^a   Vora, S ^a   Bolay, S ^a   Decosterd, L A ^a   Calandra, T ^a   Marchetti, O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMSACRINE; CARMUSTINE; CEFEPIME; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYDROCORTISONE; HYDROMORPHONE; IDARUBICIN; MELPHALAN; METHOTREXATE; MITOXANTRONE; MORPHINE; OPIATE; TRAMADOL; VORICONAZOLE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN TOXICITY; CLINICAL ARTICLE; COGNITIVE DEFECT; CONFUSION; CONSCIOUSNESS LEVEL; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HALLUCINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; MALE; MENTAL HEALTH; MYELOABLATIVE CONDITIONING; MYOCLONUS; NEUROLOGIC DISEASE; NEUROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; STATISTICAL MODEL; SYMPTOM;

ADULT; AGED; CEPHALOSPORINS; FEMALE; GLOMERULAR FILTRATION RATE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM; NEUTROPENIA; RETROSPECTIVE STUDIES;

EID: 77957353404     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01595-08     Document Type: Article

References (30)

1. Abanades, S., J. Nolla, A. Rodriguez-Campello, C. Pedro, A. Valls, and M. Farre. 2004. Reversible coma secondary to cefepime neurotoxicity. Ann. Pharmacother. 38:606-608. doi:10.1345/aph.1D322.
2. Barbey, F., D. Bugnon, and J. P. Wauters. 2001. Severe neurotoxicity of cefepime in uremic patients. Ann. Intern. Med. 135:1011.
3. Barbhaiya, R. H., S. T. Forgue, C. R. Gleason, C. A. Knupp, K. A. Pittman, D. J. Weidler, H. Movahhed, J. Tenney, and R. R. Martin. 1992. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob. Agents Chemother. 36:552-557.
4. Barbhaiya, R. H., C. A. Knupp, S. T. Forgue, G. R. Matzke, D. R. Guay, and K. A. Pittman. 1990. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin. Pharmacol. Ther. 48:268-276.
5. Bugnon, D., E. Giannoni, P. Majcherczyk, M. P. Glauser, and P. Moreillon. 2002. Pitfalls in cefepime titration from human plasma: plasma- and temperature-related drug degradation in vitro. Antimicrob. Agents Chemother. 46:3654-3656.
6. Chatellier, D., M. Jourdain, J. Mangalaboyi, F. Ader, C. Chopin, P. Derambure, and F. Fourrier. 2002. Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med. 28:214-217. doi:10.1007/s00134-001-1170-9. (Pubitemid 34293837)
7. Chow, K. M., C. C. Szeto, A. C. Hui, T. Y. Wong, and P. K. Li. 2003. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy 23:369-373.
8. Compendium Suisse des Médicaments. 2009. Arzneimittel-Kompendium der Schweiz. Documed SA, Basel, Switzerland. http://www.kompendium.ch.
9. European Committee on Antimicrobial Susceptibility Testing. 30 June 2008, accession date. Antimicrobial wild type distributions of microorganisms. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast. org.
10. Garces, E. O., M. F. Andrade de Anzambuja, D. da Silva, J. A. Bragatti, T. Jacoby, and T. F. Saldanha. 2008. Renal failure is a risk factor for cefepime-induced encephalopathy. J. Nephrol. 21:526-534.
11. Hughes, W. T., D. Armstrong, G. P. Bodey, E. J. Bow, A. E. Brown, T. Calandra, R. Feld, P. A. Pizzo, K. V. Rolston, J. L. Shenep, and L. S. Young. 2002. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34:730-751.
12. Immunocompromised Host Society. 1990. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J. Infect. Dis. 161:397-401.
13. Jallon, P., L. Fankhauser, R. Du Pasquier, A. Coeytaux, F. Picard, S. Hefft, and F. Assal. 2000. Severe but reversible encephalopathy associated with cefepime. Neurophysiol. Clin. 30:383-386.
14. Lam, S., and I. H. Gomolin. 2006. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy 26:1169-1174. doi:10.1592/phco.26.8.1169.
15. Lamoth, F., T. Buclin, A. Pascual, L. A. Decosterd, T. Calandra, and O. Marchetti. 2008. Association between high cefepime plasmid concentrations and neurotoxicity in febrile neutropenic patients with mild renal dysfunction, abstr. A-3558. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother, and 46th Ann. Meet. Infect. Dis. Soc. Am. American Society for Microbiology, Washington, DC.
16. Lipman, J., S. C. Wallis, and C. Rickard. 1999. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob. Agents Chemother. 43:2559-2561.
17. Lortholary, O., A. Lefort, M. Tod, A. M. Chomat, C. Barras-Joly, and C. Cordonnier. 2008. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect. Dis. 8:612-620. doi:10.1016/S1473-3099(08)70228-7.
18. Martinez-Rodriguez, J. E., F. J. Barriga, J. Santamaria, A. Iranzo, J. A. Pareja, M. Revilla, and C. R. la Rosa. 2001. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am. J. Med. 111:115-119.
19. National Cancer Institute. 30 June 2008, accession date. Common terminology criteria for adverse events. National Cancer Institute online guidelines. National Cancer Institute, National Institutes of Health, Bethesda, MD. http://ctep.cancer.gov/reporting/ctc.html.
20. Neu, H. C. 1996. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am. J. Med. 100:68S-75S.
21. Nguyen, T. D., B. Williams, and E. Trang. 19 February 2009, posting date. Cefepime therapy and all-cause mortality. Clin. Infect. Dis. [Epub ahead of print.] doi:10.1086/597264.
22. Pea, F., P. Viale, D. Damiani, F. Pavan, F. Cristini, R. Fanin, and M. Furlanut. 2005. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob. Agents Chemother. 49:3550-3553. doi:10.1128/AAC.49.8.3550-3553.2005.
23. Pea, F., P. Viale, and M. Furlanut. 2005. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin. Pharmacokinet. 44:1009-1034.
24. Sonck, J., G. Laureys, and D. Verbeelen. 2008. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol. Dial. Transplant. 23:966-970. doi:10.1093/ndt/gfm713.
25. Sugimoto, M., I. Uchida, T. Mashimo, S. Yamazaki, K. Hatano, F. Ikeda, Y. Mochizuki, T. Terai, and N. Matsuoka. 2003. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology 45:304-314.
26. Tam, V. H., P. S. McKinnon, R. L. Akins, G. L. Drusano, and M. J. Rybak. 2003. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob. Agents Chemother. 47:1853-1861.
27. U.S. Food and Drug Administration. 30 June 2008, accession date. Maxipime. U.S. Food and Drug Administration, Washington, DC. http://www.fda.gov/medwatch/SAFETY/2003/03MAR-PI/Maxipime-PI.pdf.
28. U.S. Food and Drug Administration. 2009. Cefepime (marketed as Maxipime) update of ongoing safety review. U.S. Food and Drug Administration, Washington, DC. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm167427.htm.
29. Verstappen, C. C., J. J. Heimans, K. Hoekman, and T. J. Postma. 2003. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63:1549-1563.
30. Yahav, D., M. Paul, A. Fraser, N. Sarid, and L. Leibovici. 2007. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect. Dis. 7:338-348. doi:10.1016/S1473-3099(07)70109-3.